Endothelin Receptor Antagonists in Cardiovascular Medicine: Challenges and Opportunities

摘要: The discovery of the release endothelium-derived vasoconstriction led to studies identifying peptide endothelin and its receptors. In early 1990s, receptor antagonists (ERAs) were developed preclinical clinical initiated. Despite strong experimental evidence for a role endothelin-1, predominant member family, in cardiovascular physiology disease, vast majority medicine using negative partly because study design and/or patient selection frequently inadequate. This chapter provides an overview system as well data ERA obtained disease models arterial hypertension, atherosclerosis, coronary artery pulmonary heart failure, renal allograft rejection following cardiac transplantation. Results developments trials will be discussed also covering reasons failed discontinuation drug development numerous ERAs.